Introduction of the biosimilar trastuzumab and its impact on patients and services

Bookmark and Share
Published: 25 Sep 2019
Views: 1129
Geoff Saunders - The Christie NHS Foundation Trust, Manchester, UK

Geof Saunders speaks to ecancer at the 2019 Biosimilars Educational Advanced Masterclass for Pharmacists (P-BEAM) in Zurich about introducing a biosimilar of trastuzumab into clinical practice.

He speaks about the processes behind the implementation of this biosimilar, which included a variety of staff across different disciplines.

Saunders also reflects on the feedback from this, especially from patients and how these processes could be improved for the future.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

If you would like to learn more about biosimilar medicines, please visit our free e-learning modules here.